Guardant Health, Inc. announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield blood test. The study met all primary endpoints, demonstrating strong performance for the updated algorithm.
The sensitivity of this new screening algorithm for detecting CRC was 84% with 90% specificity. Specifically, the sensitivity for detection of stage I CRC was 62%, providing crucial early detection capabilities.
This clinical validation reinforces the effectiveness and reliability of the Shield blood test as a primary screening option. The positive results are expected to support further commercialization efforts and broader acceptance among healthcare providers and payers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.